KR850007083A - 재조합체 인터로이킨-2의 회수방법 - Google Patents

재조합체 인터로이킨-2의 회수방법 Download PDF

Info

Publication number
KR850007083A
KR850007083A KR1019850002078A KR850002078A KR850007083A KR 850007083 A KR850007083 A KR 850007083A KR 1019850002078 A KR1019850002078 A KR 1019850002078A KR 850002078 A KR850002078 A KR 850002078A KR 850007083 A KR850007083 A KR 850007083A
Authority
KR
South Korea
Prior art keywords
process according
gel filtration
aqueous solution
butanol
high performance
Prior art date
Application number
KR1019850002078A
Other languages
English (en)
Inventor
에드워드 코쓰(외 4) 키스톤
Original Assignee
알버트 피. 할루인
세투스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24378044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850007083(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알버트 피. 할루인, 세투스 코포레이션 filed Critical 알버트 피. 할루인
Publication of KR850007083A publication Critical patent/KR850007083A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

재조합체 인터로이킴-2의 회수방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명 공정의 두가지 가능한 태양에 의해 얻어지는 생성물의 밀도계스캔(densitomenter scans)을 나타낸다. 제2도는 실시예 3의 생성물의 HPLC 크로마토그램 및 SDS-PAGE분석이다. 제3도는 실시에 9의 생성물의 HPLC 크로마토그램이다. 제4도는 IL-2를 미생물학적으로 생성하는 바람직한 진행공정의 도표이다.

Claims (7)

  1. (a) IL-2를 함유하는 형질전환된 미생물의 세포막을 파괴하고 (b) 수득된 파괴물을, 세포상 물질로부터 비 IL-2프로테인을 선택적으로 추출시키는 카오트로픽제(chaotropic agent)의 수용액으로 추출하여 (c) 추출혼합물의 고상(solid phase)중의 IL-2를 IL-2와 수용성 복합체를 형성하는 가용화제의 수용액으로 용해시킨후(이때, 이 용액은 환원제를 함유한다.), (d) 환원제의 존재하에서 생성된 용액으로부터 IL-2를 분리하는 단계로 이루어짐을 특징으로 하여, IL-2를 함유하는 형질전화된 미생물로부터 IL-2를 회수하는 방법.
  2. 제1항에 있어서, 카오트로픽제가 우레아이고 가용화제가 나트륨도데실 설페이트 또는 나트륨 라우릴사코신임을 특징으로 하는 방법.
  3. 제1 또는 2항에 있어서, 단계(b)가 염기성 pH에서 수행됨을 특징으로 하는 방법.
  4. 제1,2 또는 3항중의 어느 하나에 있어서, 단계(d)가 겔여과 또는 역상 고성능액체 크로마토그라피에 의해 수행됨을 특징으로 하는 방법.
  5. 제1,2 또는 3항중의 어느 하나에 있어서, 단계(d)가, 겔여과에 의해 용액으로부터 IL-2함유 분획을 분리하고 역상 고성능액체 크로마토그라피에 의해 이 분획으로부터 생성된 IL-2를 정제시킴으로써 수행됨을 특징으로 하는 방법.
  6. 제1,2 또는 3항중의 어느하나에 있어서, 단계(d)가, (ⅰ)2-부탄올 또는 2-메틸-2-부탄올로 단계(c)의 수용액으로부터 IL-2를 추출하고 (ⅱ)추출물로부터 IL-2를 산침전시킨후 (ⅲ)산침전된 IL-2를 겔여과로 정제시킴을 특징으로 하는 방법.
  7. 제6항에 있어서, 단계(d)후에 단계(d)의 생성물을 산화시키고, 이 산화된 생성물을 역상 고성능액체 크로마토그라피에 의해 정제시킴을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850002078A 1984-03-28 1985-03-28 재조합체 인터로이킨-2의 회수방법 KR850007083A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US594,223 1984-03-28
US06/594,223 US4569790A (en) 1984-03-28 1984-03-28 Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions

Publications (1)

Publication Number Publication Date
KR850007083A true KR850007083A (ko) 1985-10-30

Family

ID=24378044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850002078A KR850007083A (ko) 1984-03-28 1985-03-28 재조합체 인터로이킨-2의 회수방법

Country Status (21)

Country Link
US (3) US4569790A (ko)
EP (2) EP0156373B1 (ko)
JP (2) JP2599903B2 (ko)
KR (1) KR850007083A (ko)
AT (1) ATE81674T1 (ko)
AU (1) AU592751B2 (ko)
CA (1) CA1341083C (ko)
DE (2) DE3588189T2 (ko)
DK (1) DK166324C (ko)
ES (1) ES8609362A1 (ko)
FI (1) FI94960C (ko)
GR (1) GR850741B (ko)
HK (1) HK1004474A1 (ko)
IE (1) IE59100B1 (ko)
IL (1) IL74733A (ko)
IN (1) IN162903B (ko)
NO (1) NO851235L (ko)
NZ (1) NZ211569A (ko)
PH (1) PH21012A (ko)
PT (1) PT80172B (ko)
ZA (1) ZA852347B (ko)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
NZ210634A (en) * 1983-12-23 1989-05-29 Hoffmann La Roche Purification of recombinant human interleukin - 2; pharmaceutical compositions
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4656132A (en) * 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−２の製造方法
US5523215A (en) * 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US5248769A (en) * 1985-06-26 1993-09-28 Cetus Oncology Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4788144A (en) * 1985-06-28 1988-11-29 International Minerals & Chemical Corp. Fermentation process for the high level production of swine growth
US4762784A (en) * 1985-07-15 1988-08-09 International Minerals & Chemical Corp. Fermemtation process for the high level production of bovine growth hormone
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US4894330A (en) * 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US4879374A (en) * 1987-03-13 1989-11-07 Immunex Corporation Bovine interleukin-1β DNA sequence
US5108911A (en) * 1987-03-13 1992-04-28 Immunex Corporation Process for preparing bovine interleukin-Iβ
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
EP0368857B1 (en) * 1987-05-11 1997-08-06 Chiron Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
US4801691A (en) * 1987-05-15 1989-01-31 International Minerals & Chemical Corp. Method for removing sodium dodecyl sulfate from sodium dodecyl sulfate solubilized protein solutions
WO1989001046A1 (en) * 1987-07-29 1989-02-09 Schering Biotech Corporation Purification of human interleukin-4 expressed in escherichia coli
JP2669859B2 (ja) * 1987-08-04 1997-10-29 協和醗酵工業株式会社 タンパク質の再活性化法
EP0337243A1 (en) * 1988-04-14 1989-10-18 F. Hoffmann-La Roche Ag Process for purifying recombinant human interleukin-2
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
US5939524A (en) * 1991-12-09 1999-08-17 The Scripps Research Institute Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use
AU648214B2 (en) * 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
CN1051092C (zh) * 1993-05-21 2000-04-05 沈阳军区后勤部军事医学研究所 一种重组大肠杆菌培养液中分离和纯化重组人白细胞介素2的方法
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
ATE418542T1 (de) 2001-03-29 2009-01-15 Schering Corp Als ccr5-antagonisten verwendbare aryloxim- piperazine
HUP0501111A2 (en) * 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
DE602004023863D1 (de) * 2003-09-09 2009-12-10 Novartis Vaccines & Diagnostic Chromatographische auftrennung therapeutischer polypeptide
AU2004283294B2 (en) 2003-10-23 2011-03-17 Kineta Two, Llc Detection of mutations in a gene associated with resistance to viral infection, OAS1
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
DE102005005542A1 (de) * 2005-02-07 2006-08-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung von Aldesleukin für die pharmazeutische Verwendung
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
RU2304586C1 (ru) * 2006-03-27 2007-08-20 Михаил Николаевич Смирнов Препарат интерлейкина-2 и способ его получения
ES2360893T3 (es) 2006-08-16 2011-06-10 F. Hoffmann-La Roche Ag Inhibidores no nucleósidos de la transcriptasa inversa.
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
EA016386B1 (ru) 2007-05-30 2012-04-30 Ф. Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
AU2008340422B2 (en) 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US20120036767A1 (en) * 2008-08-04 2012-02-16 Larach Mario C Continuous cultivation, harvesting, and extraction of photosynthetic cultures
CA3144697A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
CN104507953B (zh) * 2012-05-31 2018-05-18 新加坡科技研究局 通过用正电性有机添加剂处理来降低蛋白质制剂中蛋白质-污染物复合物和聚集物水平的方法
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
CA3071013A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
KR20200086722A (ko) 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
CR20200546A (es) 2018-05-21 2021-05-18 Nektar Therapeutics ESTIMULADOR SELECTIVO TREG RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS
SG11202012299SA (en) * 2018-06-13 2021-01-28 Akron Biotechnology Llc Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
CN114245802B (zh) 2019-06-20 2024-10-15 石药集团巨石生物制药有限公司 修饰的il-2蛋白、peg偶联物及其用途
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
CN111676261A (zh) * 2020-06-24 2020-09-18 宁波博睿瀚达生物科技有限公司 一种高纯度重组白介素-2的制备工艺
CN111793124A (zh) * 2020-06-24 2020-10-20 宁波博睿瀚达生物科技有限公司 一种去除重组白介素-2内毒素的方法
IL313567A (en) 2021-12-14 2024-08-01 Lilly Co Eli Dose transmitters for selective TREG stimulator RUR20KD-IL-2 and related preparations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897309A (en) * 1974-02-15 1975-07-29 Merck & Co Inc Process for removing pyrogenic material from aqueous solutions
JPS6030291B2 (ja) * 1978-03-20 1985-07-16 森永乳業株式会社 人顆粒球の分化増殖を促進するｈｇｉ糖蛋白質、ｈｇｉ糖蛋白質の製造法及びｈｇｉ糖蛋白質を含有する白血球減少症治療剤
IN150740B (ko) * 1978-11-24 1982-12-04 Hoffmann La Roche
JPS55148098A (en) * 1979-05-10 1980-11-18 Toray Ind Inc Concentration and purification of interferon
CH648331A5 (de) * 1979-07-31 1985-03-15 Hoffmann La Roche Homogenes fibroblasten-interferon und dessen herstellung.
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4401756A (en) * 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
JPS58116498A (ja) * 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
CA1341562C (en) * 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US4778879A (en) * 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
DE3378128D1 (en) * 1982-04-20 1988-11-03 Sloan Kettering Inst Cancer Purification of interleukin 2
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
JPS58198293A (ja) * 1982-05-12 1983-11-18 Shionogi & Co Ltd インタ−ロイキン等免疫調節因子の製造方法
US4490289A (en) * 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
DE3242851A1 (de) * 1982-11-19 1984-05-24 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verfahren zur reinigung von menschlichen lymphokinen
JPS59116231A (ja) * 1982-12-13 1984-07-05 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 抗−インタ−ロイキン−２単クロ−ン抗体
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
AU579089B2 (en) * 1983-02-08 1988-11-17 Biogen, Inc. Human interleukin-2-like polypeptides
IL71275A0 (en) * 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4582799A (en) * 1983-04-15 1986-04-15 Damon Biotech, Inc. Process for recovering nonsecreted substances produced by cells
IL71951A0 (en) * 1983-06-01 1984-09-30 Hoffmann La Roche Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
WO1985000606A1 (en) * 1983-07-19 1985-02-14 Takeda Chemical Industries, Ltd. Human il-2 and process for its preparation
US4464295A (en) * 1983-08-17 1984-08-07 The United States Of America As Represented By The Secretary Of Agriculture Simple and rapid method for extraction of proteins from bacteria
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
GB8327880D0 (en) * 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4675383A (en) * 1983-11-15 1987-06-23 The Salk Institute For Biological Studies Purification of T-cell growth factor
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
NZ210634A (en) * 1983-12-23 1989-05-29 Hoffmann La Roche Purification of recombinant human interleukin - 2; pharmaceutical compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
DE3575072D1 (de) * 1984-03-28 1990-02-08 Cetus Corp Pharmazeutische zusammensetzungen von mikrobenerzeugtem interleukin-2.
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4782139A (en) * 1985-10-28 1988-11-01 Eli Lilly And Company Selective chemical removal of a protein amino-terminal residue
US4787658A (en) * 1986-07-29 1988-11-29 Harris Jr John Unibody bumper system
US5156968A (en) * 1988-06-24 1992-10-20 Genentech, Inc. Purified yeast ubiquitin hydrolase

Also Published As

Publication number Publication date
DK166324C (da) 1993-08-23
DK135985D0 (da) 1985-03-26
ES8609362A1 (es) 1986-09-01
HK1004474A1 (en) 1998-11-27
PH21012A (en) 1987-06-23
FI94960B (fi) 1995-08-15
JPH08332089A (ja) 1996-12-17
FI851231A0 (fi) 1985-03-27
ZA852347B (en) 1986-11-26
IL74733A0 (en) 1985-06-30
CA1341083C (en) 2000-08-15
NZ211569A (en) 1988-05-30
DK135985A (da) 1985-09-29
NO851235L (no) 1985-09-30
DK166324B (da) 1993-04-05
ATE81674T1 (de) 1992-11-15
EP0156373B1 (en) 1992-10-21
JP2648587B2 (ja) 1997-09-03
GR850741B (ko) 1985-06-26
IE59100B1 (en) 1994-01-12
ES541608A0 (es) 1986-09-01
IL74733A (en) 1990-11-05
US4569790A (en) 1986-02-11
AU592751B2 (en) 1990-01-25
EP0156373A3 (en) 1987-09-02
EP0470586A1 (en) 1992-02-12
DE3588189T2 (de) 1998-11-19
US5419899A (en) 1995-05-30
DE3586762D1 (de) 1992-11-26
PT80172B (pt) 1987-06-17
DE3588189D1 (de) 1998-08-20
EP0156373A2 (en) 1985-10-02
EP0470586B1 (en) 1998-07-15
DE3586762T2 (de) 1993-02-25
IE850799L (en) 1985-09-28
JP2599903B2 (ja) 1997-04-16
FI94960C (fi) 1995-11-27
IN162903B (ko) 1988-07-23
JPS611393A (ja) 1986-01-07
PT80172A (en) 1985-04-01
US5614185A (en) 1997-03-25
AU4046785A (en) 1985-10-03
FI851231L (fi) 1985-09-29

Similar Documents

Publication Publication Date Title
KR850007083A (ko) 재조합체 인터로이킨-2의 회수방법
PT83205B (pt) Metodo de purificacao e activacao de proteinas a partir de corpos de inclusao insoluveis
ATE156491T1 (de) Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
KR890701616A (ko) 과립구-대식세포 군체 자극 인자의 정제방법
KR930013105A (ko) 양 성장 호르몬의 정제 방법
KR950018040A (ko) Aot/이소옥탄 역마이셀계를 이용한 단백질 분리방법
KR960031478A (ko) 유비퀴틴 융합 인간 칼시토닌의 정제방법
KR930013106A (ko) 연어 성장 호르몬의 정제 방법
KR970005303A (ko) 인진쑥 단백 다당체 및 그의 추출 정제법
KR960031596A (ko) 신규의 혈전용해효소 및 이의 정제 방법
KR970010976A (ko) 대장균에서 인체 파필로마바이러스16형 e6 단백질의 분리 정제 방법 및 상기 단백질을 포함하는 자궁암 진단용 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application